Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
QAV680 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| QAV680 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Fluticasone Propionate Inhaler | ACTIVE_COMPARATOR | - |
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| QAV680 | DRUG | - |
| Matching placebo for QAV680 | DRUG | - |
| Fluticasone Propionate | DRUG | - |
| Mometasone Furoate | DRUG | - |
Inclusion criteria: * Mild to moderate persistent asthma for at least 6 months. Exclusion criteria: * Past or recent history of significant medical illness and/or lab abnormalities including but not limited to ECG abnormalities, abnormal LFT, HIV, Hep B/C, * Allergic disorders, pancreatic disease...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
QAV680 is an investigational small molecule drug developed by Novartis AG for respiratory conditions. It has been studied in Phase 2 clinical trials for asthma and seasonal allergic rhinitis. It is not an approved therapy and remains in clinical development.
QAV680 has been evaluated for the treatment of asthma and seasonal allergic rhinitis. Both are respiratory and allergic conditions, and the drug was tested in Phase 2 trials in adults with these diagnoses. It is investigational and not approved for any use.
QAV680 is a PTGDR2 antagonist. PTGDR2 is a prostaglandin D2 receptor, and QAV680 works by blocking this receptor as a small molecule antagonist. This mechanism is being explored in respiratory and allergic disease settings.
QAV680 is developed by Novartis AG, which trades under the ticker NVS. Novartis sponsored the Phase 2 clinical trials of QAV680 in asthma and seasonal allergic rhinitis.
QAV680 is in Phase 2 development. It has completed Phase 2 trials in asthma and seasonal allergic rhinitis, and it is not FDA approved. No active trials are currently listed for this asset.
QAV680 has been studied in two completed Phase 2 trials. NCT00814216 evaluated efficacy, safety and pharmacokinetics in 37 asthma patients in Germany and India. NCT00784732 compared QAV680 against placebo in 44 patients with seasonal allergic rhinitis in Canada.